Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1956 1
1959 1
1962 1
1963 2
1964 5
1965 5
1967 2
1968 12
1969 9
1970 12
1971 9
1972 10
1973 10
1974 6
1975 5
1976 4
1977 1
1978 3
1979 3
1980 7
1981 3
1982 5
1983 4
1984 3
1985 7
1986 8
1987 8
1988 10
1989 7
1990 8
1991 9
1992 16
1993 19
1994 26
1995 34
1996 37
1997 34
1998 29
1999 22
2000 32
2001 36
2002 40
2003 21
2004 24
2005 26
2006 24
2007 35
2008 25
2009 30
2010 35
2011 51
2012 25
2013 40
2014 52
2015 60
2016 55
2017 42
2018 35
2019 41
2020 41
2021 41
2022 48
2023 39
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

1,207 results

Results by year

Filters applied: . Clear all
Page 1
Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study.
Rowe SM, Zuckerman JB, Dorgan D, Lascano J, McCoy K, Jain M, Schechter MS, Lommatzsch S, Indihar V, Lechtzin N, McBennett K, Callison C, Brown C, Liou TG, MacDonald KD, Nasr SZ, Bodie S, Vaughn M, Meltzer EB, Barbier AJ. Rowe SM, et al. J Cyst Fibros. 2023 Jul;22(4):656-664. doi: 10.1016/j.jcf.2023.04.008. Epub 2023 Apr 29. J Cyst Fibros. 2023. PMID: 37121795 Clinical Trial.
BACKGROUND: MRT5005, a codon-optimized CFTR mRNA, delivered by aerosol in lipid nanoparticles, was designed as a genotype-agnostic treatment for CF lung disease. ...
BACKGROUND: MRT5005, a codon-optimized CFTR mRNA, delivered by aerosol in lipid nanoparticles, was designed as a genotype-agnostic tr …
Cystic Fibrosis Foundation Nebulizer and Compressor Accessibility Survey.
Lester M, Eidson D, Blair S, Gray S, Sapp P, Zupancic FJ, Marshall BC, Berlinski A. Lester M, et al. Respir Care. 2021 Dec;66(12):1840-1847. doi: 10.4187/respcare.09197. Epub 2021 Oct 5. Respir Care. 2021. PMID: 34610985 Free article.
BACKGROUND: Although guidelines for inhaled therapies for individuals with cystic fibrosis (CF) are available, recommendations for compressors/nebulizers to optimize care are lacking. ...
BACKGROUND: Although guidelines for inhaled therapies for individuals with cystic fibrosis (CF) are available, recommendations …
Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy.
Garcia-Contreras L, Hickey AJ. Garcia-Contreras L, et al. Adv Drug Deliv Rev. 2002 Dec 5;54(11):1491-504. doi: 10.1016/s0169-409x(02)00159-x. Adv Drug Deliv Rev. 2002. PMID: 12458157 Review.
This review addresses different aerosol therapies used to treat the underlying cause and symptoms of cystic fibrosis (CF) during the past two decades. A summary of the current methods of aerosol delivery and suggestions that may improve the efficacy of …
This review addresses different aerosol therapies used to treat the underlying cause and symptoms of cystic fibrosis (C …
Aerosolized Antibiotics.
Restrepo MI, Keyt H, Reyes LF. Restrepo MI, et al. Respir Care. 2015 Jun;60(6):762-1; discussion 771-3. doi: 10.4187/respcare.04208. Respir Care. 2015. PMID: 26070573 Free article. Review.
Administration of medications via aerosolization is potentially an ideal strategy to treat airway diseases. This delivery method ensures high concentrations of the medication in the targeted tissues, the airways, with generally lower systemic absorption and systemic advers …
Administration of medications via aerosolization is potentially an ideal strategy to treat airway diseases. This delivery method ensu …
Oxidative stress and antioxidant therapy in cystic fibrosis.
Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, Iuliano L, Piroddi M, Dechecchi MC, Cabrini G; Working Group on Inflammation in Cystic Fibrosis. Galli F, et al. Biochim Biophys Acta. 2012 May;1822(5):690-713. doi: 10.1016/j.bbadis.2011.12.012. Epub 2011 Dec 28. Biochim Biophys Acta. 2012. PMID: 22226887 Free article. Review.
Cystic fibrosis is a lethal autosomal recessive condition caused by a defect of the transmembrane conductance regulator gene that has a key role in cell homeostasis. A dysfunctional cystic fibrosis transmembrane conductance regulator impairs the efflux …
Cystic fibrosis is a lethal autosomal recessive condition caused by a defect of the transmembrane conductance regulator gene t …
Inhaled medications in cystic fibrosis beyond antibiotics.
Sepe A, Villella VR, Cimbalo C, Castaldo A, Nunziata F, Corcione A, Bona G, Maiuri L, Raia V. Sepe A, et al. Minerva Pediatr. 2019 Aug;71(4):371-375. doi: 10.23736/S0026-4946.19.05509-9. Epub 2019 Feb 13. Minerva Pediatr. 2019. PMID: 30761821 Review.
Structural lung disease begins very early in children with cystic fibrosis (CF), often in the first three months of life. Inhaled medications represent an attractive therapeutic approach in CF that are routinely used as early intervention strategies. Two aerosoli …
Structural lung disease begins very early in children with cystic fibrosis (CF), often in the first three months of life. Inha …
Cystic fibrosis microbiology: Advances in antimicrobial therapy.
Waters V, Smyth A. Waters V, et al. J Cyst Fibros. 2015 Sep;14(5):551-60. doi: 10.1016/j.jcf.2015.02.005. Epub 2015 Feb 28. J Cyst Fibros. 2015. PMID: 25737165 Free article. Review.
Much of the improvement in the survival of individuals with cystic fibrosis (CF) is due to advancements in antimicrobial treatments. New aerosolized antibiotic formulations have recently been introduced (such as inhaled aztreonam), and others are in developme …
Much of the improvement in the survival of individuals with cystic fibrosis (CF) is due to advancements in antimicrobial treat …
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Locke LW, Myerburg MM, Weiner DJ, Markovetz MR, Parker RS, Muthukrishnan A, Weber L, Czachowski MR, Lacy RT, Pilewski JM, Corcoran TE. Locke LW, et al. Eur Respir J. 2016 May;47(5):1392-401. doi: 10.1183/13993003.01880-2015. Epub 2016 Mar 23. Eur Respir J. 2016. PMID: 27009167 Free PMC article.
Cystic fibrosis subjects without P. aeruginosa had similar MCC to control subjects. ...Depressed MCC in cystic fibrosis is associated with P. aeruginosa infection. ABS is consistently increased in cystic fibrosis....
Cystic fibrosis subjects without P. aeruginosa had similar MCC to control subjects. ...Depressed MCC in cystic fibro …
Aerosolized agents for airway clearance in cystic fibrosis.
Southern KW, Clancy JP, Ranganathan S. Southern KW, et al. Pediatr Pulmonol. 2019 Jun;54(6):858-864. doi: 10.1002/ppul.24306. Epub 2019 Mar 18. Pediatr Pulmonol. 2019. PMID: 30884217 Review.
The outlook for people with cystic fibrosis (CF) has improved considerably as a result of conventional therapies including aerosolized agents for airway clearance. ...
The outlook for people with cystic fibrosis (CF) has improved considerably as a result of conventional therapies including …
Aerosol pulmonary immune engineering.
Sudduth ER, Trautmann-Rodriguez M, Gill N, Bomb K, Fromen CA. Sudduth ER, et al. Adv Drug Deliv Rev. 2023 Aug;199:114831. doi: 10.1016/j.addr.2023.114831. Epub 2023 Apr 24. Adv Drug Deliv Rev. 2023. PMID: 37100206 Free article. Review.
Aerosolization of immunotherapies poses incredible potential for manipulating the local mucosal-specific microenvironment, engaging specialized pulmonary cellular defenders, and accessing mucosal associated lymphoid tissue to redirect systemic adaptive and memory responses …
Aerosolization of immunotherapies poses incredible potential for manipulating the local mucosal-specific microenvironment, engaging s …
1,207 results